What’s Behind Biogen’s Move To Cut Prices On Its Controversial Alzheimer’s Drug Aduhelm? This week, drugmaker Biogen made a stunning announcement: It is going to cut in half the price of its controversial Alzheimer’s drug Aduhelm.